Search PubMed⌕ Search

Biomedical subjects

I R Edwards

Publications and source records attributed to I R Edwards.

114 records · Page 7Linked to original sources
PubMedDate not supplied

Adverse drug reaction reporting and retrospective phenotyping for oxidation polymorphism.

A genetically determined impairment in the ability to oxidase sparteine and debrisoquine also affects the oxidation of several other drugs. This impairment in oxidation may result in accumulation of the associated drugs and in an increased susceptibility to adverse reactions from these drugs. Dunedin houses the New Zealand national centre for the collation and study of adverse drug reactions. Included among the reporting schemes is an intensified monitoring system for newly released drugs, in which physicians report all clinical events occurring during treatment with the drugs under surveillance. The centre thus has available extensive records of names and addresses of prescribers and patients who have been reported as experiencing an adverse event while receiving drug therapy. We investigated the association between genetically poor oxidation of sparteine and adverse reactions to drugs selected as possibly sharing the sparteine/debrisoquine oxidation pathway; these included perhexiline, metoprolol, debrisoquine, piroxicam, mianserin and nifedipine. A kit containing instructions, a sparteine capsule and a container for urine collection was sent to physicians who reported adverse reactions or events to one of the above drugs for forwarding to the patient. It appeared possible, after assays of returned urine for sparteine and its metabolites, that adverse reactions to nifedipine were associated with genetically poor oxidation.(ABSTRACT TRUNCATED AT 250 WORDS)

Debrisoquin↗
PubMedDate not supplied

The accelerating need for pharmacovigilance.

The search for new drugs takes on greater complexity with increasing knowledge, allowing more sophisticated therapeutic interventions. At the same time there is increasing commercial pressure for the pharmaceutical industry to find 'blockbuster' drugs which will be marketed globally to maximise profit in the shortest possible time. Other changes in the industry--shortened times for drug development and increasing outsourcing of functions--make for an environment where some pre-marketing safety issues may go unnoticed. The increasing challenge to pharmacovigilance is not only to be able to find early signals of drug problems, but to rapidly determine the true benefits and risks. We may not have adequate systems to prevent unnecessary harm from globally marketed drugs.

Databases, Factual↗
PubMedDate not supplied

The management of adverse drug reactions: from diagnosis to signal.

Severe adverse reactions (ADR) are uncommon and benefits of drug treatment usually outweigh the disadvantages. Definitions and guidelines for managing adverse drug reactions (ADRs) are proposed mainly with the aim of helping to keep the possibility of ADR at the front of our minds and making the right diagnosis. As spontaneous reporting is a cornerstone in post-marketing surveillance, the reasons for under-reporting are thoroughly analysed. Finally, a reminder is given that communication of information should be encouraged within the medical community and that everyone who is involved in the treatment of patients has an active part to play in the network of pharmacovigilance.

Adverse Drug Reaction Reporting Systems↗